ACB should raise the offer to $28 to $30 and be done with itEven at $24, CMED would still be the cheapest revenue-producing LP that is publicly traded. That means that ACB picked VERY well when they selected CMED from the list of LP's, but they low-balled CMED shareholders on the offer. Sweeten the offer and it is done, and nobody has to hear about all this whiny legal stuff again. I think it is safe to say we have all heard enough about this merger...
BB